Oncovir, Inc.

Oncovir, Inc is dedicated to the development of Hiltonol® (PICLC) for the treatment of cancer, infectious, immune, and degenerative disorders

[Oncovir, Inc. @oncovir]

Join this COVID-19 Treatment Prevention Study at the University of Calgary! #universityofcalgarymedicine #hiltonol #COVID19 #polyiclc #Calgary #clinicaltrial

[Oncovir, Inc. @oncovir]

We have begun a Phase I study for COVID-19! The trial is being conducted at the University of Calgary and is funded via a contribution agreement from the Government of Canada under the DND IDEaS program and DRDC! #polyiclc #COVID19 #universityofcalgary
https://t.co/zpG0YNc7FR

[UCalgaryMedicine @UCalgaryMed]

Participate in research! A #UCalgaryMed research team is looking for healthy, fully vaccinated adults to join a #COVID19 treatment prevention study. Details: https://t.co/XplPUWfGY8

[Oncovir, Inc. @oncovir]

Some more exciting data on #polyiclc mechanism of action. Many thanks to the research team! #hiltonol #lungcancer
https://t.co/SENCiZn9UK

[Oncovir, Inc. @oncovir]

#polyiclc #hiltonol #cancer #immunotherapy

[ACIR @ACIR_org]

A two-alarm fire: poly-ICLC triggers two danger pathways https://t.co/KBHfl2d9va

[Oncovir, Inc. @oncovir]

Health Canada has approved Oncovir's #COVID19 #clinicaltrial for nasal application of #PolyICLC! "A Phase I-Ib, Double-blinded, Randomized Repeated Dose Multicenter, Safety and Immunogenicity Study of Nasal Poly-ICLC (#Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults"

[Ash Tewari, MD @AshTewariMD]

CO-think to co-defeat Co-VID. Thanks to Dr Nina Bharadwaj, Suji Nair and Andres Salazar for working on a intranasal immuno boosting trial for saving against COVID in prostate cancer patients- most succeptabke gender and age group for COVID complications. Hope it will be helpful.

[Parker Institute for Cancer Immunotherapy @parkerici]

1/ PICI first poster author @LeoNissolaMD presents our Phase 1b platform study at #SITC2019, Poster P387. This multi-arm, multi-stage clinical trial evaluates 3 distinct #immunotherapy drug combos in #prostatecancer. Access the PORTER poster here, https://t.co/cn2eavfop4

[Parker Institute for Cancer Immunotherapy @parkerici]

We will present our Phase 1b platform study in metastatic #prostatecancer at #SITC2019 this Friday, Poster P387. Read about our PORTER clinical trial, which tests 3 #immunotherapy drug combos. @bmsnews @cancerresearch @inoviopharma @oncovir and CellDex https://t.co/Lpq5YXmV80

[Oncovir, Inc. @oncovir]

Modulating the Tumor Microenvironment; Nina Bhardwaj, MD, PhD @sitcancer #immunotherapy #cancer #SITC2019 #immunomodulation

[Oncovir, Inc. @oncovir]

Some exciting talks coming up at the Nov 7th SITC Workshop on Intratumoral Immunomodulation! Hot is Not Enough: In Situ Vaccination to Turn Cold Tumors Hot, and Cross-Priming; Joshua Brody, MD @sitcancer @joshuabrodymd #immunotherapy #cancer #SITC2019 #immunomodulation

[Oncovir, Inc. @oncovir]

Anti-Tumor Vaccines Platforms; Esteban Celis, MD, PhD @sitcancer @estebancelis #immunotherapy #cancer #SITC2019 #immunomodulation

[Oncovir, Inc. @oncovir]

We will be at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting. The Nov 7th Pre-Conference Workshop on Intratumoral Immunomodulation is looking particularly exciting! @sitcancer #SITC2019 #oncovir #hiltonol #PICLC #immunotherapy #cancer

[Oncovir, Inc. @oncovir]

@US_FDA has cleared Oncovir's second IND application for use of Hiltonol® (Poly-ICLC). Study may proceed for treatment of prostate cancer patients scheduled for radical prostatectomy. #studymayproceed #prostatecancer #FDA #IND #Hiltonol #PICLC #immunotherapy #cancer

[Oncovir, Inc. @oncovir]

Oncovir is looking forward to participating in the 2019-2020 cohort of the NIH SBIR/STTR Commercialization Accelerator Program (CAP) with @LartaInstitute #Hiltonol #PICLC #immunotherapy #cancer #NIH #SBIR #STTR #NIHCAP